CMV disease resistant to Ganciclovir. Should valganciclovir plasma levels be monitored in high risk patients?
Enfermedad por CMV resistente a ganciclovir ¿Está indicado monitorizar niveles plasmáticos de valganciclovir en pacientes de alto riesgo ?
Read
8059
Timeswas read the article
2180
Total PDF
5879
Total HTML
| Year/Month | Html | Total | |
|---|---|---|---|
| 2025 6 | 15 | 26 | 41 |
| 2025 5 | 102 | 34 | 136 |
| 2025 4 | 74 | 20 | 94 |
| 2025 3 | 99 | 56 | 155 |
| 2025 2 | 96 | 43 | 139 |
| 2025 1 | 88 | 30 | 118 |
| 2024 12 | 60 | 33 | 93 |
| 2024 11 | 78 | 48 | 126 |
| 2024 10 | 40 | 31 | 71 |
| 2024 9 | 54 | 28 | 82 |
| 2024 8 | 85 | 56 | 141 |
| 2024 7 | 43 | 20 | 63 |
| 2024 6 | 70 | 26 | 96 |
| 2024 5 | 84 | 34 | 118 |
| 2024 4 | 47 | 23 | 70 |
| 2024 3 | 50 | 27 | 77 |
| 2024 2 | 52 | 36 | 88 |
| 2024 1 | 48 | 36 | 84 |
| 2023 12 | 58 | 30 | 88 |
| 2023 11 | 52 | 33 | 85 |
| 2023 10 | 85 | 26 | 111 |
| 2023 9 | 81 | 27 | 108 |
| 2023 8 | 71 | 26 | 97 |
| 2023 7 | 65 | 31 | 96 |
| 2023 6 | 76 | 22 | 98 |
| 2023 5 | 71 | 28 | 99 |
| 2023 4 | 58 | 15 | 73 |
| 2023 3 | 78 | 35 | 113 |
| 2023 2 | 61 | 18 | 79 |
| 2023 1 | 29 | 18 | 47 |
| 2022 12 | 45 | 27 | 72 |
| 2022 11 | 60 | 31 | 91 |
| 2022 10 | 44 | 37 | 81 |
| 2022 9 | 32 | 19 | 51 |
| 2022 8 | 47 | 37 | 84 |
| 2022 7 | 29 | 33 | 62 |
| 2022 6 | 44 | 26 | 70 |
| 2022 5 | 32 | 32 | 64 |
| 2022 4 | 38 | 29 | 67 |
| 2022 3 | 38 | 33 | 71 |
| 2022 2 | 36 | 40 | 76 |
| 2022 1 | 27 | 24 | 51 |
| 2021 12 | 35 | 35 | 70 |
| 2021 11 | 48 | 34 | 82 |
| 2021 10 | 57 | 42 | 99 |
| 2021 9 | 25 | 30 | 55 |
| 2021 8 | 25 | 36 | 61 |
| 2021 7 | 39 | 26 | 65 |
| 2021 6 | 26 | 28 | 54 |
| 2021 5 | 43 | 17 | 60 |
| 2021 4 | 85 | 48 | 133 |
| 2021 3 | 30 | 20 | 50 |
| 2021 2 | 51 | 23 | 74 |
| 2021 1 | 39 | 8 | 47 |
| 2020 12 | 28 | 6 | 34 |
| 2020 11 | 41 | 7 | 48 |
| 2020 10 | 31 | 15 | 46 |
| 2020 9 | 29 | 10 | 39 |
| 2020 8 | 43 | 13 | 56 |
| 2020 7 | 40 | 3 | 43 |
| 2020 6 | 38 | 14 | 52 |
| 2020 5 | 38 | 12 | 50 |
| 2020 4 | 28 | 11 | 39 |
| 2020 3 | 32 | 10 | 42 |
| 2020 2 | 43 | 16 | 59 |
| 2020 1 | 51 | 15 | 66 |
| 2019 12 | 51 | 22 | 73 |
| 2019 11 | 38 | 17 | 55 |
| 2019 10 | 17 | 4 | 21 |
| 2019 9 | 41 | 15 | 56 |
| 2019 8 | 32 | 18 | 50 |
| 2019 7 | 27 | 20 | 47 |
| 2019 6 | 36 | 12 | 48 |
| 2019 5 | 26 | 10 | 36 |
| 2019 4 | 54 | 27 | 81 |
| 2019 3 | 21 | 16 | 37 |
| 2019 2 | 10 | 10 | 20 |
| 2019 1 | 34 | 17 | 51 |
| 2018 12 | 42 | 21 | 63 |
| 2018 11 | 53 | 11 | 64 |
| 2018 10 | 56 | 12 | 68 |
| 2018 9 | 43 | 12 | 55 |
| 2018 8 | 27 | 10 | 37 |
| 2018 7 | 21 | 6 | 27 |
| 2018 6 | 17 | 9 | 26 |
| 2018 5 | 22 | 10 | 32 |
| 2018 4 | 17 | 4 | 21 |
| 2018 3 | 24 | 7 | 31 |
| 2018 2 | 15 | 2 | 17 |
| 2018 1 | 19 | 7 | 26 |
| 2017 12 | 25 | 7 | 32 |
| 2017 11 | 18 | 4 | 22 |
| 2017 10 | 25 | 9 | 34 |
| 2017 9 | 26 | 8 | 34 |
| 2017 8 | 24 | 5 | 29 |
| 2017 7 | 21 | 8 | 29 |
| 2017 6 | 25 | 2 | 27 |
| 2017 5 | 31 | 8 | 39 |
| 2017 4 | 21 | 8 | 29 |
| 2017 3 | 17 | 24 | 41 |
| 2017 2 | 28 | 5 | 33 |
| 2017 1 | 21 | 6 | 27 |
| 2016 12 | 46 | 4 | 50 |
| 2016 11 | 40 | 7 | 47 |
| 2016 10 | 71 | 3 | 74 |
| 2016 9 | 84 | 3 | 87 |
| 2016 8 | 127 | 2 | 129 |
| 2016 7 | 130 | 5 | 135 |
| 2016 6 | 97 | 0 | 97 |
| 2016 5 | 100 | 0 | 100 |
| 2016 4 | 80 | 0 | 80 |
| 2016 3 | 59 | 0 | 59 |
| 2016 2 | 79 | 0 | 79 |
| 2016 1 | 79 | 0 | 79 |
| 2015 12 | 90 | 0 | 90 |
| 2015 11 | 71 | 0 | 71 |
| 2015 10 | 70 | 0 | 70 |
| 2015 9 | 51 | 0 | 51 |
| 2015 8 | 71 | 0 | 71 |
| 2015 7 | 53 | 0 | 53 |
| 2015 6 | 30 | 0 | 30 |
| 2015 5 | 34 | 0 | 34 |
| 2015 4 | 5 | 0 | 5 |
Show all
